Izalontamab structure
|
Common Name | Izalontamab | ||
---|---|---|---|---|
CAS Number | 2559704-24-2 | Molecular Weight | N/A | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | N/A | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of IzalontamabIzalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer[1]. |
Name | Izalontamab |
---|
Description | Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer[1]. |
---|---|
Related Catalog | |
In Vivo | Izalontamab (5-46 mg/kg;静脉注射,每 7 天 1 次,共 4 次) 对不同类型肿瘤显示不同的抗肿瘤疗效[1]。 Animal Model: Female NOD/SCID mouse with SW48, FaDu and KYSE-150 xenografts[1] Dosage: 10, 25 and 46 mg/kg (SW48); 5, 10 and 25 mg/kg (FaDu and KYSE-150) Administration: Intravenous injection; 10, 25 and 46 mg/kg (SW48); 5, 10 and 25 mg/kg (FaDu and KYSE-150); every 7 days once, 4 doses in total Result: Dose-dependently inhibited the growth of FaDu and KYSE-150 tumors at the dose of 10 mg/kg. Inhibited 63.6% SW48 tumor growth at the dose of 46 mg/kg. |
References |
No Any Chemical & Physical Properties |